Valued at USD 6 billion in 2024, the cancer pain management market is estimated at USD 6.27 billion in 2025 and is projected to reach USD 9.3 billion by 2034, growing at a CAGR of 4.50% during the forecast period 2025–2034. Polaris Market Research identifies the rising geriatric population as a primary driver, alongside rising technology adoption in cancer pain management. Key players include BioDelivery Sciences, Daiichi Sankyo, Eli Lilly & Company, Endo Pharmaceuticals, Johnson & Johnson, Mallinckrodt Pharmaceuticals, Pfizer, Prostrakan Group, Sanofi and Teva Pharmaceuticals.

Geriatric Demand and Treatment Complexity in Cancer Pain Management

The rising geriatric population worldwide carries a higher risk of developing cancers, which has led to advances in cancer treatment, care and pain management. The impact of pain on frail older adults with cancer is substantial, and its intensity is often significant. Aging changes how medications are processed: effective dosage ranges narrow, drug elimination slows as liver and kidney function decline, receptor sites available for drug binding decrease and overall volume of distribution falls. Consequently, demand is rising for research and development of cancer pain treatments designed particularly for the geriatric population. Polaris lists this trend as the first market driver.

Complementary Therapies and Technology

Beyond medication, relaxation therapies such as tai chi, massage, yoga, hypnotherapy and meditation can benefit patients. Proper breathing techniques calm the nervous system and manage stress, hypnotherapy helps with side effects such as nausea, and massage soothes soft tissues. Demand for non-pain approaches such as acupressure, acupuncture, cognitive-behavioural therapy, music therapy and mindfulness underpins the breast cancer segment. On the technology side, a wristwatch-style device can continuously monitor heart rate, body temperature and movement, while room sensors track temperature, light, visitor movements and disruptive noises that could affect pain. The application segmentation covers immunotherapy, chemotherapy, radiotherapy and home therapy.

Browse Full Insights:

https://www.polarismarketresearch.com/industry-analysis/cancer-pain-management-market

Lung Cancer and Care Settings in the Cancer Pain Management Market

The lung cancer segment accounted for the largest market share, attributed to rising prevalence, a higher frequency of pain related to lung cancer and the presence of efficient analgesics. Treatment options have expanded due to the growing popularity of Complementary and Alternative Medicine. By end-use, hospitals dominated with a significant share, supported by patient preference for hospital settings, government initiatives to enhance healthcare infrastructure and ease of access to treatment facilities. Cancer care clinics are anticipated to grow with the fastest CAGR because they efficiently convert inputs into outputs while remaining flexible and adaptable to changing patient conditions.

Regional Outlook and Restraints

North America dominated the global market and is expected to maintain its dominance, aided by increasing cancer prevalence, technology advances, the availability of pain therapeutics and favorable healthcare infrastructure. Asia Pacific is expected to be the fastest-growing region, supported by research and development investments, strengthening healthcare infrastructure, rising per capita income, a growing elderly population and increasing prevalence of advanced chronic pain. High treatment costs remain a restraint, particularly in developing and underdeveloped countries where medication costs hinder access. Recent activity includes the January 2025 FDA approval of Journavx (suzetrigine) tablets for moderate to severe acute pain in adults, including cancer pain.

Strategic Takeaways for the Cancer Pain Management Market

Polaris Market Research frames the Cancer Pain Management market around pain type, drug type, cancer type, application, end-use and region. The report notes that properly managed pain can improve quality of life, sleep and energy levels and reduce complications associated with immobility. Participants are focusing on innovative delivery methods for advanced cancer pain and on inorganic strategies such as acquisitions, mergers, partnerships and collaborations to enhance product offerings. In July 2023, CARER and Wholeleaf joined forces to optimize the well-being of cancer patients by combining services and products. Pain-related monitoring technology, from wristwatch-style devices to room sensors, is also highlighted as an emerging area.

More Trending Latest Reports By Polaris Market Research:

Gynecological Examination Chairs Market

Fluoropolymers Market

Safari Tourism Market

Enterprise Content Management Market

Automotive Ceramics Market

Mass Flow Controller Market

Hemophilia A Treatment Market

AI Trust, Risk and Security Management Market